PRTO - Proteon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.15
+0.05 (+2.38%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.10
Open2.15
Bid2.00 x 1000
Ask2.15 x 800
Day's Range2.15 - 2.15
52 Week Range1.10 - 2.85
Volume10
Avg. Volume34,417
Market Cap38.001M
Beta1.77
PE Ratio (TTM)N/A
EPS (TTM)-2.12
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.77
Trade prices are not sourced from all markets
  • Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?
    Simply Wall St.6 days ago

    Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?

    Measuring Proteon Therapeutics Inc’s (NASDAQ:PRTO) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE11 days ago

    Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRTO as the Company's latest news hit the wire. On May 8, 2018, the Company announced that it has extended its long-term contract with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase's active pharmaceutical ingredient (API). Active-Investors.com is currently working on the research report for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), which also belongs to the Healthcare sector as the Company Proteon Therapeutics.

  • Associated Press12 days ago

    Proteon Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 34 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire12 days ago

    Proteon Therapeutics Announces First Quarter 2018 Financial Results

    “I am pleased by our team’s many accomplishments in the first quarter of 2018, which keep Proteon on track for a potential BLA filing in 2019,” said Timothy Noyes, President and Chief Executive Officer of Proteon.  “Most importantly, we completed enrollment in PATENCY-2, our ongoing Phase 3 trial of vonapanitase. PATENCY-2 is a multicenter, randomized, double-blind, placebo-controlled trial that treated 603 patients in the United States and Canada with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis.

  • GlobeNewswire13 days ago

    Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

    Proteon Therapeutics, Inc. (PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced a long-term contract extension with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient (API). “Proteon and Lonza have had a strong relationship for nearly a decade, and this amendment extends that relationship,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “Lonza’s microbial expertise and versatile assets will enable us to anticipate and deliver API for Proteon at this critical phase in the lifecycle of their therapy,” said Marc Funk, COO Lonza Pharma & Biotech.

  • Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?
    Simply Wall St.2 months ago

    Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?

    Proteon Therapeutics Inc’s (NASDAQ:PRTO): Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The US$39.64MRead More...

  • GlobeNewswire2 months ago

    Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

    WALTHAM, Mass., March 14, 2018-- Proteon Therapeutics, Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced ...

  • GlobeNewswire2 months ago

    Proteon Therapeutics to Present at Two Upcoming Investor Conferences

    WALTHAM, Mass., March 06, 2018-- Proteon Therapeutics Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced ...

  • GlobeNewswire3 months ago

    Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

    WALTHAM, Mass., March 05, 2018-- Proteon Therapeutics, Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced ...

  • Associated Press9 months ago

    Proteon Therapeutics reports 2Q loss

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 33 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...